What are the key takeaways for Pulmonx Corp ($LUNG)?

Revenue growth has turned negative, with Q1 2026 revenue of $20.6 million representing an 8.7% YoY decline as of March 31, 2026. The company continues to burn cash, reporting a Q1 2026 net loss of $13.7 million and negative free cash flow of $10.1 million. Despite top-line pressure, gross margins remain robust at 77.9%, highlighting the inherent value and pricing power of the proprietary Zephyr Valve technology.

Pulmonx Corp (LUNG) AI Stock Analysis: Earnings, Risks & Summary

Please enable JavaScript to continue using this application.

Latest Report Overview for Pulmonx Corp ($LUNG)

AI-powered analysis of Pulmonx Corp (LUNG) stock based on Q1 2026 financial data.

Published: August 4, 2026

Latest Report Overview

Pulmonx Corp (LUNG) reported For the quarterly period ended March 31, 2026 (Issuer fiscal Q1 FY2026) revenue of $20.6 million (-8.7% YoY) with a net loss of $13.7 million and diluted EPS of -$0.33. A standout KPI from the current period is the gross margin of 77.9%, which reflects the company's ability to maintain high product pricing despite volume headwinds. Management commentary focuses on the ongoing efforts to broaden the adoption of the Zephyr Valve system, despite macroeconomic and hospital-specific pressures that have dampened procedure volumes. The company continues to invest heavily in physician training and clinical education programs to overcome the steep learning curve associated with their interventional techniques, emphasizing that expanding the number of active, high-volume centers remains the primary lever for revenue growth in the near term. Operationally, the company is prioritizing cash preservation while continuing necessary R&D. Despite the revenue contraction, the balance sheet remains relatively stable with approximately $61.6 million in cash, providing a runway to support ongoing commercialization activities. However, management faces the significant challenge of reversing the recent sales deceleration while navigating the complex reimbursement landscape for interventional pulmonology.

Key Takeaways for Pulmonx Corp

Revenue growth has turned negative, with Q1 2026 revenue of $20.6 million representing an 8.7% YoY decline as of March 31, 2026.
The company continues to burn cash, reporting a Q1 2026 net loss of $13.7 million and negative free cash flow of $10.1 million.
Despite top-line pressure, gross margins remain robust at 77.9%, highlighting the inherent value and pricing power of the proprietary Zephyr Valve technology.
Pulmonx faces a high barrier to adoption, requiring persistent physician training and patient identification programs that create significant lead times for revenue realization.
The financial position remains stable for the near term with $61.6 million in cash and minimal debt ($37.3 million), though consistent losses necessitate disciplined capital allocation.

What Does Pulmonx Corp Do?

Pulmonx Corp is a medical technology company that develops and markets minimally invasive interventional pulmonology products for patients with severe lung disease, including emphysema and chronic obstructive pulmonary disease (COPD). The company's flagship offerings include the Zephyr Endobronchial Valve, a one-way valve designed to improve lung function, exercise capacity, and quality of life for patients with hyperinflation, and the Chartis Pulmonary Assessment System, a diagnostic tool that assists physicians in identifying which patients are most likely to respond to treatment. Their primary customers are hospitals, clinics, and specialized interventional pulmonologists across the United States, Europe, and Asia-Pacific. The business model is unique in that it requires both the sale of capital equipment (Chartis) and a continuous revenue stream from single-use consumable devices (Zephyr valves). Success is heavily reliant on clinical trials, regulatory approval, and the ongoing education and training of healthcare professionals to perform these specialized procedures.

Growth Drivers for Pulmonx Corp

Expansion of the active physician base through intensive training and certification programs in the US and international markets.
Increased market penetration of the Zephyr Endobronchial Valve for patients with severe COPD/emphysema, supported by long-term clinical data.
Strategic engagement with hospital networks to incorporate Zephyr Valve therapy into standard treatment pathways for COPD.
Geographic expansion into under-penetrated markets in the Asia-Pacific region.
Ongoing investment in clinical trials to broaden the potential patient population eligible for Zephyr treatment.

Overview Charts AI Summary Financials Valuation

Based on March 31, 2026

Chartloom AI Score

AI-assisted ratings across moat, quality, capital allocation, growth, and AI opportunity vs risk.

Latest Report Overview for Pulmonx Corporation ($LUNG)

Key Takeaways

1.Revenue growth has turned negative, with Q1 2026 revenue of $20.6 million representing an 8.7% YoY decline as of March 31, 2026.
2.The company continues to burn cash, reporting a Q1 2026 net loss of $13.7 million and negative free cash flow of $10.1 million.
3.Despite top-line pressure, gross margins remain robust at 77.9%, highlighting the inherent value and pricing power of the proprietary Zephyr Valve technology.
4.Pulmonx faces a high barrier to adoption, requiring persistent physician training and patient identification programs that create significant lead times for revenue realization.
5.The financial position remains stable for the near term with $61.6 million in cash and minimal debt ($37.3 million), though consistent losses necessitate disciplined capital allocation.

What They Do

How They Make Money

Pulmonx recognizes revenue primarily through the sale of medical devices and procedural kits to hospitals. The revenue model is bifurcated into capital equipment sales (Chartis console) and recurring revenue from single-use consumable disposables (Zephyr valves, delivery catheters). While the console provides an entry point into the hospital, the Zephyr valves represent the main revenue driver, with sales directly tied to the number of procedures performed. Revenue growth is driven by increasing the number of active hospital accounts, training additional physicians, and improving patient awareness to increase the number of procedures performed per site. Because the procedure is highly specialized, revenue recognition is often linked to the timing of product shipment to hospitals for scheduled procedures. The company does not operate on a subscription-based model; rather, it relies on a high-touch, volume-based model where growth is dependent on the successful, cumulative adoption of its therapy within the clinical community.

Competitive Position

Pulmonx competes primarily against other manufacturers of medical devices for respiratory health, as well as alternative treatments for COPD, including lung volume reduction surgery (LVRS), surgical options, and pharmacological therapies. Key competitors include larger medical device companies that may have broader portfolios and greater resources, as well as companies developing alternative bronchoscopic treatments. Competitive advantages cited by the company include the extensive clinical data supporting the Zephyr Valve, including the LIBERATE clinical trial, and its status as a minimally invasive alternative to traditional surgery. However, the company faces significant competition for hospital budget allocation and physician attention. Financially, the company’s heavy R&D spend and ongoing losses contrast with larger, profitable medical device peers, making it more vulnerable to market volatility and capital constraints. Sustainability is balanced: while the company holds strong, specialized intellectual property (IP), the reliance on physician training means its position can be disrupted by newer, easier-to-use technologies or changes in medical standard-of-care guidelines.

Business Strategy & Moat

Pulmonx's strategy centers on creating a 'standard of care' for emphysema treatment through robust clinical evidence and physician education. Their moat is constructed primarily of intangible assets—specifically their extensive, proprietary clinical data and the specialized training barrier that creates a high degree of physician 'stickiness' and institutional habit once a hospital is integrated into their ecosystem. Switching costs are moderate; once a hospital invests in the Chartis system and trains staff, they are unlikely to switch, but the primary barrier is the initial adoption hurdle. Capital allocation is heavily skewed toward R&D and commercial infrastructure to support market development. The strategy relies on a flywheel where clinical evidence leads to reimbursement, which drives adoption, which in turn fuels further clinical data collection. If this flywheel slows, as seen in the recent revenue decline, the moat's durability is tested, emphasizing the need for continued investment in market awareness to maintain long-term relevance.

Industry Outlook

The medical device industry, particularly in interventional pulmonology, is characterized by long product development cycles and high barriers to entry due to regulatory scrutiny and the necessity of clinical data. Macroeconomic factors such as hospital staffing shortages, budget constraints, and the rising cost of healthcare impact the adoption of new, specialized procedures. However, the aging global population and the high prevalence of COPD suggest a large, underserved addressable market. Regulatory landscapes are strict, and the company must navigate reimbursement policies that vary significantly by geography, which can act as both a tailwind and a hurdle for rapid growth. In the near term, the sector faces headwinds from increased scrutiny on elective procedures and potential shifts in hospital capital expenditure priorities, placing a premium on companies that can demonstrate both clinical efficacy and cost-effectiveness for hospital providers.

Growth Drivers

•Expansion of the active physician base through intensive training and certification programs in the US and international markets.
•Increased market penetration of the Zephyr Endobronchial Valve for patients with severe COPD/emphysema, supported by long-term clinical data.
•Strategic engagement with hospital networks to incorporate Zephyr Valve therapy into standard treatment pathways for COPD.
•Geographic expansion into under-penetrated markets in the Asia-Pacific region.
•Ongoing investment in clinical trials to broaden the potential patient population eligible for Zephyr treatment.

Recent Developments

•Maintained a stable cash position of $61.6 million as of March 31, 2026, to navigate the challenging macroeconomic environment.
•Continued implementation of cost-management strategies to align operating expenses with the recent slowdown in revenue growth.
•Refocused commercial efforts on high-volume accounts to maximize efficiency and procedure throughput.
•Ongoing participation in medical conferences and clinical symposia to sustain physician interest and clinical adoption.
•Managing supply chain and regulatory compliance to ensure consistent product availability across all regions.

Catalysts

•Release of new long-term clinical data that could support expanded reimbursement coverage.
•Positive updates from ongoing international clinical initiatives aiming to increase market access.
•Updates to major respiratory medical society guidelines that may include Zephyr Valve therapy as a recommended treatment.
•Potential changes in reimbursement policies in key international markets that could facilitate broader adoption.

RPO & Key Performance Indicators

•Revenue decreased 8.7% YoY in Q1 2026, highlighting the current challenges in driving procedure volume growth.
•Gross margin remained strong at 77.9%, suggesting sustained pricing power despite the decline in procedure counts.

Strengths

•High gross margins (77.9% in Q1 2026) demonstrate the premium nature of the proprietary Zephyr Valve technology.
•Strong clinical backing through rigorously designed trials provides a competitive advantage and supports regulatory/reimbursement efforts.
•The Zephyr Valve represents a first-of-its-kind minimally invasive therapy for a large patient population, establishing a distinct market position.
•The Chartis system provides a diagnostic advantage that simplifies the patient selection process for physicians, aiding in therapy adoption.

Risks & Concerns for Pulmonx Corporation ($LUNG)

You're one step away

Unlock the full risk analysis

See business risks, AI filing insights, and deeper research for this stock. Create a free account to continue — includes a 14-day Pro trial.

No card required • Free plan stays after trial

About this summary

AI-generated research for Pulmonx Corporation (LUNG, filings period ending March 31, 2026). AI summaries, reports, and scoring can be inaccurate or incorrect; accuracy and correctness are not guaranteed. Informational only; not investment advice or personalized guidance.Enumerated risk factors in this view may be abbreviated for anonymous or guest sessions. Full risk sections are available with full access.

Summary generated on Aug 4, 2026.

Peers of Pulmonx Corporation (LUNG)